Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00149-X
{"title":"Sommaire","authors":"","doi":"10.1016/S0987-7983(24)00149-X","DOIUrl":"10.1016/S0987-7983(24)00149-X","url":null,"abstract":"","PeriodicalId":39683,"journal":{"name":"Journal de Pediatrie et de Puericulture","volume":"37 5","pages":"Page v"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143099035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00147-6
{"title":"Page de titre","authors":"","doi":"10.1016/S0987-7983(24)00147-6","DOIUrl":"10.1016/S0987-7983(24)00147-6","url":null,"abstract":"","PeriodicalId":39683,"journal":{"name":"Journal de Pediatrie et de Puericulture","volume":"37 5","pages":"Page i"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143098494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00156-7
R. Cohen , N. Ouldali , A. Rybak
The introduction of pneumococcal conjugate vaccines (PCV) in the early 2000s had a major impact on public health, both in terms of the incidence of infections and antibiotic prescriptions. Rapidly adopted in the USA with remarkable effectiveness, 7-valent PCV was then introduced in Europe and the UK. In France, implementation has been more gradual, and the impact of this vaccination has been less obvious due to rapid serotype replacement, despite the efficacy of the vaccine serotypes. Here, we present efficacy results for France, based on time-series studies of pneumococcal meningitis, invasive pneumococcal infections, pneumonia and pleuropneumonia, acute otitis media and invasive infections in adults.
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00155-5
R. Cohen , A. Rybak , C. Levy , S. Bonacorsi , E. Varon
Since the early 1990s, pneumococcal resistance to antibiotics has grown to became a major public health issue worldwide and in France. It particularly affects the most frequently carried serotypes, and varies according to disease, age, region and the β-lactam prescribed. This article describes the factors that influence antibiotic resistance, as well as the evolution of β-lactam and macrolide resistance in pneumococci isolated from the nasopharyngeal flora of children with acute otitis media.
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00153-1
R. Cohen , C. Levy , N. Ouldali , S. Bonacorsi , E. Varon
The nasopharyngeal microbiota represents a complex ecosystem made up of several hundred bacterial species, f ve of which are frequently associated with paediatric infections: Streptococcus pneumoniae (Sp), Haemophilus influenzas (Hi), Moraxelle catarrhalis (Mc), Streptococcus pyogenes and Staphylococcus aureus (SA), and will be discussed here.
The introduction of pneumococcal conjugate vaccines, however, represented a veritable ecological revolution in the respiratory tract microbiota, altering the carriage of pneumococci, causing vaccine serotypes to be replaced by other, less pathogenic serotypes, and reducing both invasive and non-invasive infections.
The impact of vaccination programs with conjugate vaccines, carriage in healthy children and in children with acute otitis media are reported here through a study of over 20,000 children over the past 25 years.
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00148-8
{"title":"Comité de Rédaction","authors":"","doi":"10.1016/S0987-7983(24)00148-8","DOIUrl":"10.1016/S0987-7983(24)00148-8","url":null,"abstract":"","PeriodicalId":39683,"journal":{"name":"Journal de Pediatrie et de Puericulture","volume":"37 5","pages":"Page ii"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143099034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00158-0
R. Cohen , C. Levy , E. Varon
The implementation of pneumococcal conjugate vaccines (PCV7 and PCV13) in children has led to a dramatic reduction in vaccine-type pneumococcal infections, with additional benefits for adults through herd immunity. However, serotypes 3, 19A, and 19F persist at low levels in children, and new non-vaccine serotypes (NVTs) now predominate in IPD. Among the new pneumococcal vaccines approved in Europe, PCV20 covers more than 40% of invasive isolates, compared to less than 10% for PCV15. Some NVTs like 24F, not included in PCV20, remain problematic. The choice of future vaccines will depend on their ability to cover these replacement serotypes.
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00150-6
R. Cohen , E. Varon
{"title":"Éditorial","authors":"R. Cohen , E. Varon","doi":"10.1016/S0987-7983(24)00150-6","DOIUrl":"10.1016/S0987-7983(24)00150-6","url":null,"abstract":"","PeriodicalId":39683,"journal":{"name":"Journal de Pediatrie et de Puericulture","volume":"37 5","pages":"Pages 5S1-5S3"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143099036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/S0987-7983(24)00154-3
R. Cohen , C. Levy , E. Varon
All pneumococcal serotypes can be found both in carriage and various pneumococcal diseases. However, some serotypes are more frequently observed in pneumococcal infections than in carriage, suggesting an higher disease potential. The spectrum of disease induced by each serotype varies considerably: some serotypes are primarily associated with pneumonia, while others are more frequently implicated in meningitis or other specific infections. Respiratory viruses play a crucial role in triggering pneumococcal infections, particularly respiratory syncytial virus and influenza viruses. Once again, virus-bacteria cooperation varies according to serotype and viruses.
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号